Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort - Scheiner, Bernhard; Kirstein, Martha M.; Hucke, Florian; Finkelmeier, Fabian; Schulze, Kornelius; von Felden, Johann; Koch, Sandra; Schwabl, Philipp; Hinrichs, Jan B.; Waneck, Fredrik; Waidmann, Oliver; Reiberger, Thomas; et al. (Alimentary pharmacology & therapeutics, 2019)
Keywords: Aged; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - therapeutic use; Apoptosis; Austria; Carcinoma, Hepatocellular - drug therapy; Cell death; Diarrhea; Disease control; Female; Germany; Hepatitis; Hepatocellular carcinoma; Humans; Immunotherapy; Liver cancer; Liver Neoplasms - drug therapy; Male; Middle Aged; Monoclonal antibodies; Nivolumab - therapeutic use; Original; Pembrolizumab; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death Protein‐1 Targeted Immunotherapy for Hepatocellular Carcinoma; Proteins; Pruritus; Retrospective Studies; Safety; Targeted cancer therapy; Austria; Germany